Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Inventory Workdowns To Continue Through 2005, ABC Says

Executive Summary

AmerisourceBergen expects pharmaceutical manufacturer inventory destocking observed during the first quarter of 2005 to continue through the year

You may also be interested in...



Wholesalers Benefit From Fee-Based Contracts, But Speculative Buying Not Extinct

Shifting to fee-for-service agreements with pharmaceutical companies has benefited wholesalers improving cash flow, although it appears they have not entirely abandoned speculative buying

Wholesalers Benefit From Fee-Based Contracts, But Speculative Buying Not Extinct

Shifting to fee-for-service agreements with pharmaceutical companies has benefited wholesalers improving cash flow, although it appears they have not entirely abandoned speculative buying

Wholesalers Beginning To Maximize Value Of Fee-For-Service Deals

As AmerisourceBergen gains more experience with its fee-for-service distribution contracts with manufacturers, the firm is beginning to maximize the potential value of the agreements

Related Content

Topics

UsernamePublicRestriction

Register

PS045770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel